ClinicalTrials.Veeva

Menu

Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing

J

Ji Kon Ryu

Status

Unknown

Conditions

Biliary Tract Cancer

Treatments

Diagnostic Test: Endoscopic retrograde cholangiopancreatogram

Study type

Observational

Funder types

Other

Identifiers

NCT03718897
1808-056-964

Details and patient eligibility

About

The purpose of this study is to investigate genetic mutations affecting prognosis using whole genome sequencing in patients with biliary tract cancer.

Full description

Recently, as genome technology such as next-generation sequencing has progressed, precision medicine using genetic analysis in lung cancer, colorectal cancer, and melanoma has been actively studied. The need for such precision medicine is also increasing in biliary tract cancer patients. Although whole genome sequencing is relatively costly, it is known to provide more accurate information than other methods such as exome analysis and RNA sequencing in identifying promoter mutations, regulatory regions, and structural variants. Pancreatic cancer and melanoma have been studied by whole genome sequencing, but there is no previous study using whole genome sequencing method in biliary tract cancer.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients diagnosed with biliary tract cancer via endoscopic retrograde cholangiopancreatogram

Exclusion criteria

  • Pregnancy
  • Other active tumors within 5 years
  • Coagulopathy
  • Severe mental illness

Trial contacts and locations

1

Loading...

Central trial contact

Ji Kon Ryu, MD, phD; Min su You, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems